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Abstract: miR-122, an abundant liver-speciﬁc microRNA
(miRNA), regulates cholesterol metabolism and promotes hepatitis
C virus (HCV) replication. Reduced miR-122 expression in hepatocel-
lular carcinoma (HCC) correlates with metastasis and poor progno-
sis. Nevertheless, the consequences of sustained loss of function of
miR-122 in vivo have not been determined. Here, we demonstrate
that deletion of mouse Mir122 resulted in hepatosteatosis, hepatitis,
and the development of tumors resembling HCC. These pathologic
manifestations were associated with hyperactivity of oncogenic
pathways and hepatic inﬁltration of inﬂammatory cells that produce
pro-tumorigenic cytokines, including IL-6 and TNF. Moreover, deliv-
ery of miR-122 to a MYC-driven mouse model of HCC strongly inhib-
ited tumorigenesis, further supporting the tumor suppressor activity
of this miRNA. These ﬁndings reveal critical functions for miR-122 in
the maintenance of liver homeostasis and have important therapeu-
tic implications, including the potential utility of miR-122 delivery
for selected patients with HCC and the need for careful monitoring
of patients receiving miR-122 inhibition therapy for HCV.
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Abstract: MicroRNA-122 (miR-122), which accounts for 70% of the
liver’s total miRNAs, plays a pivotal role in the liver. However, its
intrinsic physiological roles remain largely undetermined. We dem-
onstrated that mice lacking the gene encoding miR-122a (Mir122a)
are viable but develop temporally controlled steatohepatitis, ﬁbrosis,
and hepatocellular carcinoma (HCC). These mice exhibited a striking
disparity in HCC incidence based on sex, with a male-to-female ratio
of 3.9:1, which recapitulates the disease incidence in humans.
Impaired expression of microsomal triglyceride transfer protein
(MTTP) contributed to steatosis, which was reversed by in vivo resto-
ration of Mttp expression. We found that hepatic ﬁbrosis onset can be
partially attributed to the action of a miR-122a target, the Klf6 tran-
script. In addition, Mir122a/ livers exhibited disruptions in a range
of pathways, many of which closely resemble the disruptions found in
human HCC. Importantly, the reexpression of miR-122a reduced dis-
ease manifestation and tumor incidence in Mir122a/ mice. This
study demonstrates that mice with a targeted deletion of the Mir122a
gene possess several key phenotypes of human liver diseases, which
provides a rationale for the development of a unique therapy for
the treatment of chronic liver disease and HCC.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Hepatocellular carcinoma (HCC) is the ﬁfth most prevalent
and the third leading cause of cancer death worldwide. Although
early-stage tumors can be curated using surgical approaches,
treatment options for advanced HCC are limited. Virus- and alco-
hol-induced cirrhosis represent major causes of HCC, but the
molecular mechanisms underlying HCC are still only incom-
pletely understood [1]. Several microRNAs (miRNAs) have been
implicated in hepatocarcinogenesis and may represent promising
new anti-cancer targets (reviewed in [2]). miRNAs are small
non-coding regulatory RNAs resulting from Dicer-mediated
processing of miRNA precursors. They act by modulating target
messenger RNA translation and/or stabilization and are
involved in a wide variety of biological processes. miR-122, a13 vol. 58 j 821–823
International Hepatology
miRNA predominantly expressed in hepatocytes, accounts for
approximately 70% of liver-expressed miRNAs. Evidence from
sequestrating miR-122 in vivo suggests that this miRNA is
involved in cholesterol biosynthesis and liver function [3]. It
may also play a role in hepatocarcinogenesis as its expression
is downregulated in HCC [4] and hepatocyte-speciﬁc Dicer1
knockout (KO) mice spontaneously develop HCC [5]. However,
its exact role in hepatocarcinogenesis and the underlying
molecular mechanisms had not been investigated yet.
Two independent laboratories now report arresting conclu-
sions regarding the metabolic, anti-inﬂammatory, and anti-
tumorigenic roles of miR-122, by generating germline KO, called
either Mir122 KO [6] or Mir122a/ [7], and liver-speciﬁc KO
(Mir122 LKO) mice [6]. These mice developed normally and were
characterized by reduced serum cholesterol levels in line with
previous studies reporting antisense miR-122 sequestration
in vivo [3]. In Mir122 KO and Mir122 LKO mice, total serum cho-
lesterol was reduced by 30% with concomitant decrease in LDL
and HDL while TG levels remained unchanged [6]. Reduced
serum cholesterol (total cholesterol, VLDL and HDL) was also
observed in Mir122a/ along with reduced TG levels [7]. In con-
trast to antisense miR-122-treated mice, these Mir122 KO mice
developed steatosis and hepatitis that progressed to ﬁbrosis
and HCC and thereby displayed a phenotype resembling liver-
speciﬁc Dicer1 KO mice [5] (Table 1). Hepatic gene expression
analysis indicated that numerous genes involved in lipid metab-
olism were differentially regulated in LKO mice [6]. Mir122a/
mice also demonstrated impaired expression of several proteinsTable 1. Phenotype ofMir122 knockout mice and effect ofMir122 restoration. This ta
LKO mice [6,7]. n.d., not determined; mo, months; wk, week.
Mir122 KO and Mir122 LKO mice [6]
Development and fertility Normal
Serum lipids Reduced total cholesterol, LDL, HDL (V
Normal TG
ALP and ALT
Serum inflammation markers
Elevated ALP (ALT n.d.)
Elevated IL-6, TNFα
Liver histology Extensive lipid accumulation
Reduced glycogen storage
Inflammation (infiltrating inflammatory c
expressing Ccr2 and producing IL-6 an
increase of Ccl2 expression in hepatoc
Fibrosis
Proliferation of bile duct
Spontaneous tumors (higher in LKO m
mo; equal penetration in KO males and
ter 11-15 mo but males display higher t
and grades)
Hepatic lipid metabolism Elevated TG
Upregulated expression of TG biosynth
pat1, Mogat1, Agpat3, Agpat9, Ppap2a
and Dgat1)
Abnormal expression of genes involved
ment, cellular proliferation and death, a
(Epcam, c-Myc, Mapre1 and Rhoa)
Rescue of liver pathology and 
serum lipids
n.d.
Prevention of HCC Restoration of liver miR-122 expression
adenoviral delivery in 11-wk-old mice
822 Journal of Hepatology 201involved in lipid metabolism, among which microsomal triglycer-
ide transfer protein (MTTP). Although miR-122 does not directly
target MTTP messenger RNA, prolonged injection of MTTP- or
miR-122-expression constructs in Mir122a/ mice allowed res-
toration of MTTP levels, increase of serum lipids and reduction
of hepatic steatosis, inﬂammation and ﬁbrosis [7]. These func-
tional experiments indicate that lack of MTTP and/or miR-122
expression leads to liver disease. In addition, both groups vali-
dated several novel direct targets of miR-122, among which
Klf6 or Agpat1, that could also account for the observed pheno-
type [6,7].
Moreover, in both models, prolonged lack of miR-122 in
mouse hepatocytes associates with HCC [6,7]. While spontaneous
tumors were 3.9-fold higher in male Mir122a/ mice than in
females [7], in line with observed HCC incidence in humans,
Hsu et al. observed equal penetration in Mir122 KO males and
females although males displayed higher tumor weight and
grades [6]. To ascertain that lack of miR-122 indeed accounts
for HCC development, the authors elegantly demonstrated
through in vivo rescue experiments that tumor development
may be prevented by restoration of hepatic miR-122 expression
[6,7]. These experiments provide deﬁnite conclusions regarding
the tumor suppressor function of miR-122 in the liver.
Noteworthy, HCC-resembling tumors were associated with
hepatic inﬁltration of inﬂammatory cells and increased levels of
pro-inﬂammatory/pro-tumorigenic cytokines such as IL-6 and
TNFa [6,7]. In order to assess whether the anti-inﬂammatory
function of miR-122 may be dissociated from its tumorble summarizes the characteristics ofMir122a/ as well asMir122 KO and Mir122
Mir122a-/- mice [7]
Normal
LDL n.d.) Reduced total cholesterol, HDL, VLDL (LDL n.d.)
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ells
d TNFα, 
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esis (Ag-
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 in develop-
nd cancer 
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Foxa1, Foxa2, Mlxipl and Nr1h2)
Increased expression of genes involved in immune 
response, fibrogenesis (Klf6), epithelial-mesenchy-
mal transition, signal transduction, cell survival, cell 
death, and cancer
Restoration of MTTP or miR-122 expression by 
hydrodynamic injection
 by Restoration of miR-122 expression in 3-mo-old 
mice by hydrodynamic injection
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suppressor function, Hsu et al. used a previously described non-
inﬂammatory HCC mouse model (tet-o-MYC; LAP-tTA mice) [8].
Interestingly, miR-122 levels were markedly reduced in tumors
from these mice and adenoviral-mediated delivery of miR-122
strongly reduced tumor burden in treated mice [6]. Thus, these
experiments clearly demonstrate that miR-122 possesses an
anti-tumorigenic function that is independent of its role in pre-
venting liver disease and inﬂammation.
In conclusion, these new mouse models provide an important
step forward in the understanding of HCC development. These
data clearly conﬁrm an important role of miR-122 in hepatocar-
cinogenesis. Further studies are needed to explore the tumor sup-
pressor function of miR-122. These results have also profound
implications regarding the therapeutic potential of miR-122.
While they indicate that complementing the low expression of
miR-122 could be a valid strategy against HCC, it is important
to note that miR-122 is also an essential host factor for hepatitis
C virus (HCV) replication [9]. In contrast to the physiological role
of miR-122 in negatively regulating expression of proteins
involved in lipid metabolism, miR-122 positively regulates HCV
translation and replication. Antiviral strategies targeting miR-
122 are therefore in clinical development [10]. Given that chronic
HCV infection is a major cause of HCC, the fact that miR-122 acts
as a tumor suppressor in hepatocytes will have to be taken into
account for the treatment of chronic HCV infection.Conﬂict of interest
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